Atellica Ci 1900

Siemens Healthineers launches Atellica CI Analyzer

Siemens Healthineers has recently introduced its latest addition to the Atellica in vitro diagnostics portfolio, the Atellica CI Analyzer. This advanced analyzer, designed for immunoassay and clinical chemistry testing, has obtained FDA clearance and is now accessible in numerous major markets around the world. Specifically tailored for labs operating at low to medium testing volumes, the Atellica CI Analyzer offers various competitive advantages, including improved predictability of turnaround time, enhanced reporting functionality, and prioritized safety and security measures.

Regardless of their size, every laboratory faces significant challenges due to labor shortages, from ensuring reliable test results for predictable patient care to safeguarding staff, protecting data, and achieving environmental objectives. The Atellica CI Analyzer provides a solution for both standalone labs and satellite labs within broader health networks, equipping them with the same reagents, consumables, and intelligent software found in the company’s flagship Atellica Solution. Moreover, the new analyzer boasts a compact footprint of only 1.9 square meters, making it an ideal fit for smaller laboratories.

Sharon Bracken, the head of Diagnostics for Siemens Healthineers, emphasized the importance of workflow standardization and clinical equivalence in successful laboratory operations within health networks. She praised the Atellica CI Analyzer for elevating laboratory operations to a new level of agility. With rapidly changing testing demands, labs today require testing instrumentation and informatics that can keep pace effortlessly. The next-generation laboratory analyzer is designed to anticipate workflow bottlenecks, proactively mitigate them, and provide insights based on data to help laboratory staff perform their jobs more effectively and efficiently.

Dr. Mustafa Serteser, CEO of Acibadem Labmed Clinic Laboratories and a Siemens Healthineers customer, praised the Atellica CI Analyzer as a best-in-class approach for mid- or low-volume laboratories. The analyzer addresses critical concerns such as space preservation, staff allocation per analyzer, turnaround time, and cost-effective usage of reagents.

The Atellica CI Analyzer incorporates thoughtful engineering with unique capabilities to optimize downtime and increase lab efficiency and profitability. It features random access sampling, micro-volume aspiration, and automatic maintenance and quality control scheduling, enabling labs to provide more predictable sample turnaround times. Additionally, the chemistry and immunoassay engines run independently, ensuring that throughput remains unaffected if one of the two needs to stop.

Apart from delivering patient results, labs must meet reporting requirements, address cybersecurity concerns, and prioritize staff satisfaction. To assist with these challenges, the Atellica CI Analyzer comes equipped with the Atellica Laboratory Evaluation Suite, which delivers inspection-ready reports. This eliminates the need for additional software and allows laboratory staff to focus their time on other critical lab operations. Moreover, the analyzer offers user authentication, role-based authorizations, and audit trails to enhance security measures.

With plans to offer a menu of over 200 assays across 20 disease states, each lab within a health network can choose the most suitable tests for its patient population, meeting the ever-growing demand and fulfilling the clinical needs of patients. More than 50 key assays are capable of delivering results in under 14 minutes, further enhancing the efficiency and effectiveness of the laboratory’s operations.

© Siemens Healthineers

Post a comment

Your email address will not be published. Required fields are marked *

Recent News

Successful completion of the inaugural shoulder arthroplasty surgeries utilizing Stryker’s Blueprint® Mixed Reality Guidance System occurred at Mayo Clinic in Minnesota and St. Joseph’s Health Care in London, Canada.

Medical Device Technologies Market is projected to increase from USD 4.20 Billion in 2022 to USD 16.32 Billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 18.50% over the forecast period

Hodess Cleanroom Construction expands its cleanroom services capabilities with the acquisitions of Protocol Management Services and Clean Rooms West

Medtronic Will Invest Up to $75 Million And begin Co-Promotion For CathWorks’ FFRangio System In The U.S. Europe and Japan

Tornier Shoulder Arthroplasty Portfolio Introduced by Stryker, With New Tornier Perform Humeral System Launched in Europe